中文摘要：

目的制备载碱性成纤维细胞生长因子（bFGF）甲基丙烯酸缩水甘油酯修饰葡聚糖纳米凝胶微球，观察其对新生血管生成的诱导和促进作用。方法采用改良乳液聚合法制备载bFGF纳米微球（bFGF-Dex-GMA-NPs），对纳米微球的外形、包封率、体外释药特征进行常规检测，建立兔后肢缺血模型后，分为以下几组（每组6只）：安慰剂治疗组（注射磷酸盐缓冲液）（A组）；bFGF治疗组（B组）；载bFGF纳米微球组（C组），分别于治疗后7、21d用^99mTc标记的sestamibi对后肢血流进行分析，并于21d将动物处死，取局部肌肉组织切片进行免疫组织化学染色，镜下对毛细血管计数。结果合成的纳米微球外形圆整，无相互粘连，包封率高达80．9％，并能较好地控制bFGF的释放，持续释放时间超过25d。后肢缺血模型治疗第7天，B组和C组能量计数分别为（130．95±14．59）、（127．60±11．36），明显高于A组（27．65±6．82）（P〈0．05），但B组和C组间差异无统计学意义（P〉0．05），第21天，C组能量计数增加到（450．69±21．06），明显高于A组（39．89±8，45）和B组（165．34±15，88）（P〈0．05）。免疫组织化学染色结果显示C组毛细血管密度是（99.00±5.44）／mm^2，明显高于其他两组2．00±0.59（A组）、13．00±1.35（B组）（P〈0．05）。结论载bFGF纳米微球可以控制bFGF长时间释放，对缺血组织新生血管形成有优于单纯bFGF的诱导和促进作用。

英文摘要：

Objective To evaluate the efficiency of angiogenesis of basic fibroblast growth factor （bFGF） released from dextran-glycidyl methacrylate （Dex-GMA） nanoparticles. Methods bFGF-DEX- GMA-NPs were prepared by improved emulsion polymerization method. Its morphology, size and size distribution, encapsulated ratio and release characteristics in vitro were assessed by routine procedures. Three therapies were done on rabbit hindlimb ischemic models which were divided into three groups accordingly： group treated with PBS （group A） ; group treated with free bFGF （group B） ; group treated with bFGF-Des-GMA-NPs （group C）. To evaluate the efficiency of angiogenesis in each group, ^99mTc- labelled sestamibi scanning at the day 7 and 21 post-surgery, and immunohistochemistry staining were also done to measure the capillary density. Results The shape of bFGF-dex-GMA-NPs was spherical and the encapsulated ratio was 80.9%. The release profile of this nanoparticulate carder in vitro was in accord with two phase＇s kinetics law and the release period was longer than 25 days. 99mTe-labelled sestamibi scanning at 21st day presented a significant enhanced angiogenesis efficiency in group C （450.69 ± 21.06） as compared with groups A and B （39.89 ± 8.45, 165.34 ± 15.88, respectively） （ P 〈 0.05）. The immunohistochemistry staining revealed the capillary density in group C was （99.00 ± 5.44 ）/mm^2, which was significantly greater than in group A （2.00 ± 0.59） and group B （ 13.00 ± 1.35） （P 〈 0.05）. Conclusion bFGF-Dex-GMA-NPs, a novel controlled release system of bFGF, is long-term and stable, which can be used as an angiogenesis enhancer in tissue regeneratation and engineering area.